Protective effects of caffeoylquinic acids on the aggregation and neurotoxicity of the 42-residue amyloid β-protein.

[1]  Takao Kaneko,et al.  SOD1 (Copper/Zinc Superoxide Dismutase) Deficiency Drives Amyloid β Protein Oligomerization and Memory Loss in Mouse Model of Alzheimer Disease* , 2011, The Journal of Biological Chemistry.

[2]  L. Gravitz.  Drugs: A tangled web of targets , 2011, Nature.

[3]  H. Isoda,et al.  Structure-activity relationship of caffeoylquinic acids on the accelerating activity on ATP production. , 2011, Chemical & pharmaceutical bulletin.

[4]  H. Isoda,et al.  3,4,5-tri-O-caffeoylquinic acid inhibits amyloid β-mediated cellular toxicity on SH-SY5Y cells through the upregulation of PGAM1 and G3PDH , 2011, Cytotechnology.

[5]  C. Lippa.  Review of Issue: Alzheimer’s Caregiver’s and Internet-Based Support Services: Do They Work? , 2011 .

[6]  H. Isoda,et al.  Neuroprotective effect of 3,5-di-O-caffeoylquinic acid on SH-SY5Y cells and senescence-accelerated-prone mice 8 through the up-regulation of phosphoglycerate kinase-1 , 2010, Neuroscience.

[7]  B. Winblad,et al.  Alzheimer's disease: clinical trials and drug development , 2010, The Lancet Neurology.

[8]  J. Dordick,et al.  Resveratrol Selectively Remodels Soluble Oligomers and Fibrils of Amyloid Aβ into Off-pathway Conformers* , 2010, The Journal of Biological Chemistry.

[9]  T. Shirasawa,et al.  Identification of Physiological and Toxic Conformations in Aβ42 Aggregates , 2009, Chembiochem : a European journal of chemical biology.

[10]  D. Ehrnhoefer,et al.  EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers , 2008, Nature Structural &Molecular Biology.

[11]  D. Selkoe,et al.  Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.

[12]  M. Yoshimoto,et al.  Growth suppression of human cancer cells by polyphenolics from sweetpotato (Ipomoea batatas L.) leaves. , 2007, Journal of agricultural and food chemistry.

[13]  M. Clifford,et al.  Profiling the chlorogenic acids and other caffeic acid derivatives of herbal chrysanthemum by LC-MSn. , 2007, Journal of agricultural and food chemistry.

[14]  K. Bae,et al.  Antioxidant activity of caffeoyl quinic acid derivatives from the roots of Dipsacus asper Wall. , 2006, Journal of ethnopharmacology.

[15]  Tsuyoshi Hamaguchi,et al.  Anti-amyloidogenic effects of antioxidants: implications for the prevention and therapeutics of Alzheimer's disease. , 2006, Biochimica et biophysica acta.

[16]  Ehud Gazit,et al.  Inhibition of Amyloid Fibril Formation by Polyphenols: Structural Similarity and Aromatic Interactions as a Common Inhibition Mechanism , 2006, Chemical biology & drug design.

[17]  Y. Akao,et al.  Identification of caffeoylquinic acid derivatives from Brazilian propolis as constituents involved in induction of granulocytic differentiation of HL-60 cells. , 2005, Bioorganic & medicinal chemistry.

[18]  M. Nagao,et al.  Formation and stabilization model of the 42-mer Abeta radical: implications for the long-lasting oxidative stress in Alzheimer's disease. , 2005, Journal of the American Chemical Society.

[19]  A. Farah,et al.  Effect of roasting on the formation of chlorogenic acid lactones in coffee. , 2005, Journal of agricultural and food chemistry.

[20]  M. Nagao,et al.  Analysis of the Secondary Structure of β-Amyloid (Aβ42) Fibrils by Systematic Proline Replacement* , 2004, Journal of Biological Chemistry.

[21]  P. Aisen,et al.  Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant. , 2004, Biochemical and biophysical research communications.

[22]  Shubo Han,et al.  The Flavonoid Baicalein Inhibits Fibrillation of α-Synuclein and Disaggregates Existing Fibrils* , 2004, Journal of Biological Chemistry.

[23]  William M. Mauck,et al.  Increased plaque burden in brains of APP mutant MnSOD heterozygous knockout mice , 2004, Journal of neurochemistry.

[24]  Colin L. Masters,et al.  Neurodegenerative diseases and oxidative stress , 2004, Nature Reviews Drug Discovery.

[25]  M. Nagao,et al.  Neurotoxicity and physicochemical properties of Abeta mutant peptides from cerebral amyloid angiopathy: implication for the pathogenesis of cerebral amyloid angiopathy and Alzheimer's disease. , 2003, The Journal of biological chemistry.

[26]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[27]  M. Nagao,et al.  Synthesis, aggregation, neurotoxicity, and secondary structure of various A beta 1-42 mutants of familial Alzheimer's disease at positions 21-23. , 2002, Biochemical and biophysical research communications.

[28]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[29]  Ehud Gazit,et al.  A possible role for π‐stacking in the self‐assembly of amyloid fibrils , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  D. Butterfield,et al.  Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. , 2000, Journal of structural biology.

[31]  Claudio Soto,et al.  β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy , 1998, Nature Medicine.

[32]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[33]  G. Glenner,et al.  Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein , 1984 .

[34]  George Perry,et al.  Oxidative stress and neurotoxicity. , 2008, Chemical research in toxicology.

[35]  F. Gejyo,et al.  Kinetic analysis of amyloid fibril formation. , 1999, Methods in enzymology.

[36]  D. Teplow,et al.  Amyloid (cid:1) -Protein Assembly and Alzheimer Disease * □ S , 2022 .